Navigation Links
NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
Date:11/3/2008

Patient adoption of daily home therapy continues to grow; Positive data supports broader acceptance within ESRD community.

LAWRENCE, Mass., Nov. 3 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that 3,000 end-stage renal disease (ESRD) patients are now prescribed to receive therapy using its NxStage(R) System One(TM), the first truly portable home hemodialysis machine. This latest milestone represents 35% growth in patient adoption since the end of 2007. The NxStage System One is now available at hundreds of dialysis centers in markets throughout the United States.

"We are pleased by the continuing, annual increase in patient adoption of daily home hemodialysis (DHD) with the NxStage System One," said Jeff Burbank, President and Chief Executive Officer of NxStage Medical, Inc. "This validates our strategy to build sustained growth by working closely with patients and their care-providers in key markets while continuing to broaden nationwide access. It is exciting to see how DHD with the NxStage System One is benefiting the lives of patients. The latest significant evidence of this impact are the just-released interim results of our landmark FREEDOM study, which show that NxStage's DHD therapy significantly improves patients' health-related quality-of-life in terms of recovery time, depressive symptoms and overall health-related quality-of-life, in comparison with conventional, thrice-weekly in-center hemodialysis treatment."

The NxStage System One is the first truly portable hemodialysis system cleared for home use by the FDA. Unlike traditional dialysis equipment, the System One plugs into a standard electrical outlet, requires no special infrastructure to operate and is easy to use by trained patients accompanied by their trained partners. Rather than commuting to and from a dialysis clinic three times per week for scheduled treatment sessions lasting three to four hours, patients who use the NxStage System One have the personal freedom to conduct prescribed treatments at home on their own schedule and to bring the System with them when they travel. The System One works in concert with NxStage's PureFlowTM SL dialysate preparation system, a compact, easy-to-use system that prepares high-purity dialysate from regular tap water, helping to make daily home hemodialysis even more practical and accessible to patients. The PureFlow SL eliminates the need for bagged dialysate in the home, while still allowing patients to use bagged fluids when they travel.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

About End-Stage Renal Disease

End-stage renal disease is the permanent failure of the kidneys to filter the body's wastes. It is most commonly caused by diabetes, hypertension, or genetic disorders. In order to survive, ESRD patients must use some form of therapy to replace the function of the kidneys for the rest of their lives. Currently, over 450,000 patients in the United States suffer from ESRD, and the costs of treating ESRD patients are over $20 billion annually in the U.S. Due to increases in diabetes, hypertension, and the aging of the U.S. population, those figures are projected to double within the next 10-15 years. The most common form of kidney replacement therapy in the United States today is hemodialysis, which is used by over 350,000 patients. The great majority of these patients are treated with conventional, in-center hemodialysis, in which they must travel to a nearby dialysis center three times per week, where they are connected to dialysis machines for treatments lasting approximately three to four hours, to cleanse their blood.

About Hemodialysis

Today, most patients undergo hemodialysis therapy three times a week in outpatient dialysis centers. This differs significantly from the 24/7 workings of the naturally functioning kidney. Increasingly, clinicians and patients have recognized opportunities for therapy improvements with more frequent, or daily, dialysis. Hundreds of clinical papers have reported on the health and quality of life benefits of hemodialysis done more frequently. The reported benefits include reduced hypertension, reduced cardiac strain and left ventricular hypertrophy, reduced amyloid disease, and improved anemia status, appetite, and quality of life, including the ability to return to work. A summary of the literature discussing these benefits can be found on NxStage's website, http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to: expected growth in home daily hemodialysis and market acceptance of the NxStage System One, anticipated growth in ESRD patient numbers, the anticipated impact and results of the FREEDOM study and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact

Kristen Sheppard

NxStage Medical, Inc.

ir@nxstage.com

978-332-5923

Media Contact

Jim Weinrebe

Schwartz Communications, Inc.

nxstage@schwartz-pr.com

781-684-0770


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
2. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
3. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
4. ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module.
5. Rochester Medical Implants Achieves ISO 13485:2003 Certification for Medical Device Manufacturing
6. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
7. MD On-Line Achieves CAQH CORE(TM) Certification for Consistent Healthcare Administrative Data Exchange
8. iCAD Achieves Record-High Ratings in Mammography CAD User Satisfaction
9. Echocardiography Lab at Presbyterian Hospital of Dallas Achieves Prestigious Reaccreditation
10. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
11. Companion Data Services Achieves ISO Certification for Quality Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , ... February 09, 2016 , ... ... helping businesses recover after a disaster, announced today the acquisition of Hawaii DKI. ... Hawaii. , “Investing in like-minded companies who excel at service and ...
(Date:2/9/2016)... Cambridge, MA (PRWEB) , ... February 09, 2016 ... ... Institute (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for ... medical services covered in the report, Evaluation of the 2015 Fee Schedule ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... 10, 2016 , ... The Journal of Pain Research has published ... .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet little ... chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb.8, 2016 Cardiac Assist ... Summary GlobalData,s Medical Devices sector report, " ... 2015 " provides an overview of Cardiac Assist ... provides comprehensive information on the pipeline products with ... of development. The report reviews major players involved ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... Devices - Medical Devices Pipeline Assessment, 2015 Summary ... Medical Devices Pipeline Assessment, 2015" provides an overview of ... This report is prepared using data sourced from in-house ... industry experts. *Note: Certain sections in the report ... and relevance of data in relation to the equipment ...
Breaking Medicine Technology: